All In Biotech

Drug Trial Radar · NCT00617747

Efficacy and Tolerability of Zolmitriptan Nasal Spray

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (ZOMIG) Nasal Spray in the Acute Treatment of Adult Subjects With Migraine.

Last checked: Nov 20, 2026Latest source record: Apr 6, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,114 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,114

Actual

Start

Sep 2002

Primary completion

Not stated

Study completion Jun 2003

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness and tolerability (the ability not to experience ill effects from the study drug) of a zolmitriptan nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches for up to 12 weeks in adult subjects with migraine headaches

Conditions

  • Migraine

Interventions

  • ZolmitriptanDrug

    5mg Nasal Spray

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement in migraine headache pain from severe or moderate to mild or noneTime frame: 15 minutes after the initial dose of trial treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.